FDA seeks permanent future for rare pediatric priority review vouchers
The US Food and Drug Administration (FDA) is seeking to permanently authorise the rare pediatric disease priority review voucher (PRV)…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into…
-
Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s…
-
Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first…
-
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to $7.8bn, solidifying the drugmaker’s status as…
-
Podcast: European biotech rallies against US and China powerhouses
As Lisbon played host to BIO Europe Spring, an annual conference that brings together professionals across the global biotech sector,…
-
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
The US Food and Drug Administration (FDA) has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) in leukocyte adhesion deficiency type I…
-
FDA opens door to feedback on ‘unclear’ national priority voucher pathway
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National…
-
MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement
MSD will buy cancer specialist Terns Pharmaceuticals in a deal worth $6.7bn, as the drugmaker continues its string of multibillion-dollar…
-
J&J wins FDA approval for Icotyde to enter psoriasis pill market
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) Icotyde (icotrokinra) for the treatment of plaque…